Episode 24: Samsara Biocapital's Srini Akkaraju
BioVenture VoiCes with Chris Garabedian
00:00
iBio and opportunistic outcomes
Srini reflects on iBio's sale to Merck, strategic choices and trade-offs between independence and partnering with big pharma.
Play episode from 47:03
Transcript
